Page 40 - MBCA_FULL REPORT_FINAL_FOR_WEB

Trial Category No. of Trials No. of Drugs No. of No. of No. of No. of
under Study* Phase I Phase Phase II Phase
I/II III

Targeted Trials Assigned to Hallmark of
Cancer Category (n=162)
7. Tumor-Promoting Inflammation
(n=0) 0 0 0 0 0 0
Selective Anti-inflammatory Agents 0 0 0 0 0 0
8. Deregulating Cellular Energetics
(n=0) 1 1 1 0 0 0
9. Activating Invasion and Metastasis
(n=1)
10. Avoiding Immune Destruction
(n=27) 27** 25 12 5 8 0
Total 18 18 8 4 4 0
Vaccines 9 7 4 1 4 0
Immunomodulators
11. Other Targeted Trials (n=7) 7 5 2 2 3 0
Total 4 2 1 1 2 0
Heat Shock Protein 3 3 1 1 1 0
Other
Trials of Nontargeted Therapies (n=35) 35 37 15 4 13 3
Total 4 4 2 1 1 0
Cancer Stem Cells 28 30 12 3 11 2
Chemotherapy 3 3 1 0 1 1
Surgery/Other 0 0 0 0 0 0
Supportive Care
Site-Specific Trials (n=20) 20** 20 1 4 11 1
Total 17 17 1 3 9 1
Brain 1 1 0 0 1 0
Bone 1 1 0 0 1 0
Liver 1 1 0 1 0 0
Liver/Lung 1 1 0 0 1 0
Abbreviations: Akt = a serine/threonine-specific protein kinase; ErB = another term for ErbB, the epidermal growth factor receptor protein
family; HDAC = histone deacetylase; IAP = inhibitors of apoptosis protein family; IGF = insulin-like growth factor; JAK = Janus kinase family;
Notch = family of proteins involved in intracellular signaling; PARP = poly-ADP ribose polymerase; PTEN = phosphatase and tensin homolog;
RAF/MEK/ERK/ALK = a key cellular signaling pathway; VEGF = vascular endothelial growth factor.
* Some agents are being tested in multiple trials; other trials are testing combinations of drugs.
**Six trials did not list the phase.

40